Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Follicular Lymphoma
Sponsor: Kite Pharma Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU0210
U.S. Govt. ID: NCT05371093
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: You are being invited to take part in a research study that includes studying an experimental treatment named axicabtagene ciloleucel, referred to as axi-cel. The experimental treatment would involve removing some of your immune cells, genetically engineering those cells to identify cancer, receiving additional therapy while you wait for those cells to be released, and then infusing those cells back and assessing the effect on your cancer cells. The purpose of this main study is to determine if the experimental treatment, axi-cel, is safe and effective in treating your relapsed or refractory follicular lymphoma, compared to standard-of-care therapy. What treatment you receive will be randomly assigned (like tossing a coin), and you will have a 50% chance to receive axi-cel. You and your Study Doctor will know if you are receiving axi-cel or standard of care therapy. If you are randomized into the experimental treatment group, you will have one course of axi-cel treatment. Standard of care therapy may include Rituximab/Bendamustine (BR), Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (R-CHOP), or Rituximab/Lenalidomide (R2) as selected by your Study Doctor.
This study is closed
Ran Reshef, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with follicular lymphoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator